Gland Pharma Limited
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model…
What Gland files
- Others76
- Investor Meet74
- Important27
- Updates23
- Board Meeting11
- PPTs6
Gland Pharma delivered solid Q1 FY27 results with revenue jumping 20% YoY to ₹1,800.3 Cr and Net Profit soaring 47% YoY to ₹317 Cr. Adjusted EBITDA margin improved to 28%. Both CDMO and B2B segments showed robust growth, contributing almost equally to revenue. The US market, a major revenue driver,...
Gland Pharma delivered a strong Q4 FY26, with revenue up 22% YoY to ₹1,742.8 Cr and full-year revenue hitting ₹6,430.7 Cr (up 14% YoY). Adjusted PAT soared 97% in Q4 to ₹366.7 Cr, reaching ₹1,045.5 Cr for FY26 (up 50% YoY). Consolidated Adj. EBITDA margin improved to 30% in Q4....
Gland Pharma delivered a solid Q3 FY26! Consolidated revenue hit ₹1,695.4 Cr, up 22% YoY, with 9M revenue at ₹4,687.9 Cr (+12%). Adjusted Profit After Tax (PAT) soared 37% YoY to ₹279.7 Cr for the quarter. US sales jumped 19% YoY, and Europe sales grew 54% YoY, while the Cenexi...
Gland Pharma reported a solid Q2 FY26, with consolidated revenue increasing 6% YoY to ₹1,486.9 Cr and profit (PAT) rising 12% YoY to ₹183.7 Cr. The company's gross profit margin improved to 63%. Strong performance in the US market saw revenue grow 10% YoY to ₹827.9 Cr, while Europe also...
Here is the summary based on your preferences: **1. Financial Highlights:** Gland Pharma's Q1 FY26 consolidated revenue rose 7% YoY to ₹1,505.6 Cr. PAT jumped 50% YoY to ₹215.5 Cr (14% margin), with EBITDA hitting ₹367.8 Cr (24% margin). Cenexi notably achieved breakeven EBITDA. The company holds a strong net...